Award details

Molecular engineering of high activity multifunctional biometallic catalysts for clickable chemistries

Reference	BB/R010412/1
Principal Investigator / Supervisor	Professor Jonathan Lloyd
Co-Investigators / Co-Supervisors	Dr Jennifer Cavet, Professor Royston Goodacre, Professor Nicholas Turner
Institution	The University of Manchester
Department	Earth Atmospheric and Env Sciences
Funding type	Research
Value (£)	724,952
Status	Current
Type	Research Grant
Start date	01/03/2018
End date	01/06/2023
Duration	63 months

Abstract

Aims BioMetCat will deliver a novel extension of synthetic biology, using a combination of new microbial strains to synthesise nano-scale inorganic catalysts, stabilised against agglomeration problems that beset traditional manufacture, and augmented by highly tunable and adapted biocatalysts in hybrid "biometallic" systems to deliver clickable chemistry reactions. Key Deliverables from this project will include; (1) new microbial strains optimised to synthesise highly catalytically active metallic NPs, (2) new information on the range of industrially important reactions that can be catalyzed by metallic bioNPs, including Cu-NPs and precious metal-NPs, (3) novel tandem "biometallic" catalysts for multistep click chemistries, (4) new SERS monitoring techniques optimised for industrial biotechnology and (5) improved knowledge of microbial metal resistance mechanisms. These outputs will be documented in high impact publications and support new industrial links fostered by the vibrant BBSRC NIBB communities, extending from the IB to the environmental sectors.

Summary

BioMetCat brings together a unique group of world-renowned academics to develop an entirely new approach to making high value chemicals for a range of industries (including pharmaceuticals), in the vibrant and rapidly developing area of "industrial biotechnology". Using naturally occurring bacteria, that have been genetically manipulated to accumulate nano-scale clusters of with powerful catalytic metals, alongside enzymes that can transform target chemicals, we will produce novel "biometallic catalysts" that can potentially transform strategic areas of the high value UK chemicals sector. The work will be based on complementary skills of biologists, chemists and analysts, using the latest techniques from biology and the physical sciences and will develop novel solutions, that can turn waste metal streams into high value materials for a wide range of industries via simple "one-pot" processes that are currently not available.

Impact Summary

This proposal will address key industrial challenges currently bottlenecking commercial activities. These will include novel "one-pot" and tandem/multi-step processes retro-fittable onto conventional or existing chemistries, minimising catalyst losses, extending catalyst lifetimes and potentially generating value products from wastes (e.g. Cu-containing wastewaters). These challenges restrict ALL chemical industries, i.e. representing ubiquitous (and pressing) needs to develop novel reactions, extending structures available to the pharmaceutical industry and the agrochemicals & fine/specialty sectors. The importance of addressing these challenges is illustrated by the prediction that the proportion of IB processes within industrial chemistry is thought to increase to 20% by 2015 (Source: Horizon 2020 EU Framework Programme). The PI and CoI collaborate extensively with representatives of many major UK and other international phamaceutical companies, and also mining and water industries, and we will maximize our impact into these industries using (1) contacts developed in the BBSRC NIBBs, to which we belong and (2) the Centre of Excellence for Biocatalysis, Biotransformations and Biomanufacture (CoEBio3) of which Turner is director. Given the importance of these sectors to the UK, improved processes will make a clear contribution to economic competitiveness. Relevant UK government stakeholders also derive benefit in general from successful developments in Industrial Biotechnology, as these help to publicise the benefits of investing in IB and also inform the development of future policy, and to facilitate this we will communicate outputs through various routes including Bioscience KTN activities. Finally, we will engage with the wider public to inform them of our progress. As consumers of pharmaceutical products (and fine chemcials), the public benefits from the more efficient production of these materials, and also from the development of new products that can be accessed using new technology. Public engagement will use established programmes developed within our groups, including school visits and events at science festivals and blogging activities as well as media engagement and political engagement will be fostered via SET for Britain and Science in Parliament. Milestones and measures of success will include: Destination of PDRAs- we have a strong track record of developing the career paths of our PDRAs and PhDs, including senior positions in industry and academia. Closer engagement with industry including potential project partners such as Johnson Matthey (catalyst production), the chemical and phamaceutical industries, and water/mining companies with metallic waste streams (Cu, precious metals) that require treatment/revalorization. Development of clear follow-on funding opportunities and IP development as appropriate.

Committee	Research Committee D (Molecules, cells and industrial biotechnology)
Research Topics	Industrial Biotechnology, Microbiology, Synthetic Biology
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search